Avalyn Pharma Inc. (NASDAQ:AVLN) Given Average Recommendation of "Buy" by Analysts

Key Points

• Analysts collectively rate Avalyn Pharma “Buy,” with two buy, two strong-buy, and one hold recommendation. The average 12-month price target is $59, ranging from $51 to $80.
• Avalyn reported a quarterly loss of $21.83 per share, missing the consensus estimate of a $16.38 loss; analysts expect a full-year loss of $3.45 per share.
• The stock opened at $35.46, near its 52-week high of $35.84, giving the clinical-stage biopharmaceutical company a market capitalization of approximately $1.57 billion.

Avalyn Pharma Inc. (NASDAQ:AVLN - Get Free Report) has been assigned a consensus rating of "Buy" from the five research firms that are covering the stock, Marketbeat reports. One analyst has rated the stock with a hold recommendation, two have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $59.00.

A number of equities research analysts have recently commented on the stock. Jefferies Financial Group started coverage on shares of Avalyn Pharma in a research note on Monday, May 25th. They issued a "buy" rating and a $52.00 price objective on the stock. Wall Street Zen raised shares of Avalyn Pharma to a "hold" rating in a research note on Saturday, May 9th. Zacks Research upgraded shares of Avalyn Pharma to a "hold" rating in a report on Wednesday, May 27th. Guggenheim started coverage on shares of Avalyn Pharma in a research report on Monday, May 25th. They set a "buy" rating and a $80.00 price target on the stock. Finally, Evercore assumed coverage on Avalyn Pharma in a report on Tuesday, May 26th. They set an "outperform" rating and a $51.00 price target for the company.

Avalyn Pharma Stock Performance

Avalyn Pharma stock opened at $35.46 on Wednesday. The business has a 50 day moving average of $29.49. The firm has a market capitalization of $1.57 billion and a price-to-earnings ratio of -1.62. Avalyn Pharma has a one year low of $24.15 and a one year high of $35.84.

Avalyn Pharma (NASDAQ:AVLN - Get Free Report) last released its earnings results on Wednesday, June 3rd. The company reported ($21.83) earnings per share for the quarter, missing analysts' consensus estimates of ($16.38) by ($5.45). As a group, analysts predict that Avalyn Pharma will post -3.45 EPS for the current year.

Institutional Investors Weigh In On Avalyn Pharma

A hedge fund recently bought a new stake in Avalyn Pharma stock. Bank of New York Mellon Corp purchased a new stake in Avalyn Pharma Inc. (NASDAQ:AVLN - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 40,140 shares of the company's stock, valued at approximately $1,321,000. Bank of New York Mellon Corp owned 0.09% of Avalyn Pharma as of its most recent filing with the Securities & Exchange Commission.

About Avalyn Pharma

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source